{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T20:28:12Z","timestamp":1781468892544,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>We performed a post hoc, subgroup analysis of a phase 3, randomized, double-blind, placebo-controlled study of erenumab for prevention of episodic migraine (STRIVE) to determine the efficacy and safety of erenumab in women with self-reported menstrual migraine.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Patients received placebo, erenumab 70\u2009mg, or erenumab 140\u2009mg subcutaneously once monthly during the 6-month double-blind treatment phase of STRIVE. Women who reported history of menstrual migraine and who were\u2009\u2264\u200950\u2009years old were included in the analysis. Endpoints were change from baseline in monthly migraine days (MMD) and monthly acute migraine-specific medication days (MSMD; among patients who took acute migraine-specific medications at baseline), proportion of patients achieving \u2265\u00a050% reduction from baseline in MMD, and incidence of adverse events.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Among 814 women enrolled in STRIVE, 232 (28.5%) reported a history of menstrual migraine and were\u2009\u2264\u200950\u2009years old. Of the 232 patients, 214 (92%) had a baseline MMD\u2009&gt;\u20095, suggesting a high proportion of women with attacks outside of the 5-day perimenstrual window (2\u2009days before and 3\u2009days after the start of menstruation). Information on \u201cmigraine days\u201d includes (and does not discriminate between) perimenstrual and intermenstrual migraine attacks. Between-group differences from placebo over months 4\u20136 for erenumab 70\u2009mg and 140\u2009mg were\u2009\u2212\u20091.8 (<jats:italic>P<\/jats:italic>\u2009=\u20090.001) and\u2009\u2212\u20092.1 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) days for MMD and\u2009\u2212\u20091.6 (<jats:italic>P<\/jats:italic>\u2009=\u20090.002) and\u2009\u2212\u20092.4 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) days for acute MSMD, respectively. The odds of having a\u2009\u2265\u200950% reduction from baseline in MMD over months 4\u20136 were 2.2 (<jats:italic>P<\/jats:italic>\u2009=\u20090.024) and 2.8 (<jats:italic>P<\/jats:italic>\u2009=\u20090.002) times greater for erenumab 70\u2009mg and 140\u2009mg, respectively, than for placebo. Erenumab had an overall safety profile comparable to placebo.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Data from this subgroup analysis of women with menstrual migraine are consistent with data from the overall STRIVE episodic migraine population, supporting the efficacy and safety of erenumab in women who experience menstrual migraine.<\/jats:p>\n<jats:p>Trial registration: ClinicalTrials.gov, NCT02456740. Registered 28 May 2015.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s10194-020-01167-6","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T12:06:34Z","timestamp":1596456394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Efficacy and safety of erenumab in women with a history of menstrual migraine"],"prefix":"10.1186","volume":"21","author":[{"given":"Jelena M.","family":"Pavlovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Paemeleire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"G\u00f6bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Bonner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Kagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Mikol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"key":"1167_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/1756285609335537","volume":"2","author":"EA Macgregor","year":"2009","unstructured":"Macgregor EA (2009) Menstrual migraine: therapeutic approaches. Ther Adv Neurol Disord 2:327\u2013336. https:\/\/doi.org\/10.1177\/1756285609335537","journal-title":"Ther Adv Neurol Disord"},{"key":"1167_CR2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1046\/j.1468-2982.2003.00516.x","volume":"23","author":"EG Couturier","year":"2003","unstructured":"Couturier EG, Bomhof MA, Neven AK, van Duijn NP (2003) Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia 23:302\u2013308. https:\/\/doi.org\/10.1046\/j.1468-2982.2003.00516.x","journal-title":"Cephalalgia"},{"key":"1167_CR3","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/j.1526-4610.2010.01625.x","volume":"50","author":"EA MacGregor","year":"2010","unstructured":"MacGregor EA, Victor TW, Hu X, Xiang Q, Puenpatom RA, Chen W, Campbell JC (2010) Characteristics of menstrual vs nonmenstrual migraine: a post hoc, within-woman analysis of the usual-care phase of a nonrandomized menstrual migraine clinical trial. Headache 50:528\u2013538. https:\/\/doi.org\/10.1111\/j.1526-4610.2010.01625.x","journal-title":"Headache"},{"key":"1167_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/j.1468-2982.2004.00741.x","volume":"24","author":"F Granella","year":"2004","unstructured":"Granella F, Sances G, Allais G, Nappi RE, Tirelli A, Benedetto C, Brundu B, Facchinetti F, Nappi G (2004) Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia 24:707\u2013716. https:\/\/doi.org\/10.1111\/j.1468-2982.2004.00741.x","journal-title":"Cephalalgia"},{"key":"1167_CR5","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1177\/0333102409359315","volume":"30","author":"B Pinkerman","year":"2010","unstructured":"Pinkerman B, Holroyd K (2010) Menstrual and nonmenstrual migraines differ in women with menstrually-related migraine. Cephalalgia 30:1187\u20131194. https:\/\/doi.org\/10.1177\/0333102409359315","journal-title":"Cephalalgia"},{"key":"1167_CR6","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1177\/0333102415575723","volume":"35","author":"KG Vetvik","year":"2015","unstructured":"Vetvik KG, Benth JS, MacGregor EA, Lundqvist C, Russell MB (2015) Menstrual versus non-menstrual attacks of migraine without aura in women with and without menstrual migraine. Cephalalgia 35:1261\u20131268. https:\/\/doi.org\/10.1177\/0333102415575723","journal-title":"Cephalalgia"},{"key":"1167_CR7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s13760-017-0802-y","volume":"117","author":"B G\u00fcven","year":"2017","unstructured":"G\u00fcven B, G\u00fcven H, \u00c7omo\u011flu S (2017) Clinical characteristics of menstrually related and non-menstrual migraine. Acta Neurol Belg 117:671\u2013676. https:\/\/doi.org\/10.1007\/s13760-017-0802-y","journal-title":"Acta Neurol Belg"},{"key":"1167_CR8","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1111\/j.1526-4610.2005.00242.x","volume":"45","author":"VT Martin","year":"2005","unstructured":"Martin VT, Wernke S, Mandell K, Ramadan N, Kao L, Bean J, Liu J, Zoma W, Rebar R (2005) Defining the relationship between ovarian hormones and migraine headache. Headache 45:1190\u20131201. https:\/\/doi.org\/10.1111\/j.1526-4610.2005.00242.x","journal-title":"Headache"},{"key":"1167_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s10194-015-0503-y","volume":"16","author":"JM Pavlovic","year":"2015","unstructured":"Pavlovic JM, Stewart WF, Bruce CA, Gorman JA, Sun H, Buse DC, Lipton RB (2015) Burden of migraine related to menses: results from the AMPP study. J Headache Pain 16:24. https:\/\/doi.org\/10.1186\/s10194-015-0503-y","journal-title":"J Headache Pain"},{"key":"1167_CR10","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"key":"1167_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10194-010-0197-0","volume":"11","author":"KG Vetvik","year":"2010","unstructured":"Vetvik KG, MacGregor EA, Lundqvist C, Russell MB (2010) Self-reported menstrual migraine in the general population. J Headache Pain 11:87\u201392. https:\/\/doi.org\/10.1007\/s10194-010-0197-0","journal-title":"J Headache Pain"},{"key":"1167_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1046\/j.1468-2982.1990.1006305.x","volume":"10","author":"EA MacGregor","year":"1990","unstructured":"MacGregor EA, Chia H, Vohrah RC, Wilkinson M (1990) Migraine and menstruation: a pilot study. Cephalalgia 10:305\u2013310. https:\/\/doi.org\/10.1046\/j.1468-2982.1990.1006305.x","journal-title":"Cephalalgia"},{"key":"1167_CR13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1177\/0333102413507637","volume":"34","author":"KG Vetvik","year":"2014","unstructured":"Vetvik KG, Macgregor EA, Lundqvist C, Russell MB (2014) Prevalence of menstrual migraine: a population-based study. Cephalalgia 34:280\u2013288. https:\/\/doi.org\/10.1177\/0333102413507637","journal-title":"Cephalalgia"},{"key":"1167_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/14656566.2017.1414182","volume":"19","author":"G Allais","year":"2018","unstructured":"Allais G, Chiarle G, Sinigaglia S, Benedetto C (2018) Menstrual migraine: a review of current and developing pharmacotherapies for women. Expert Opin Pharmacother 19:123\u2013136. https:\/\/doi.org\/10.1080\/14656566.2017.1414182","journal-title":"Expert Opin Pharmacother"},{"key":"1167_CR15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/0333102410378049","volume":"31","author":"G Allais","year":"2011","unstructured":"Allais G, Sanchez del Rio M, Diener HC, Benedetto C, Pfeil J, Schauble B, van Oene J (2011) Perimenstrual migraines and their response to preventive therapy with topiramate. Cephalalgia 31:152\u2013160. https:\/\/doi.org\/10.1177\/0333102410378049","journal-title":"Cephalalgia"},{"key":"1167_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1129-2377-14-66","volume":"14","author":"RE Nappi","year":"2013","unstructured":"Nappi RE, Merki-Feld GS, Terreno E, Pellegrinelli A, Viana M (2013) Hormonal contraception in women with migraine: is progestogen-only contraception a better choice? J Headache Pain 14:66. https:\/\/doi.org\/10.1186\/1129-2377-14-66","journal-title":"J Headache Pain"},{"key":"1167_CR17","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1046\/j.1468-2982.2000.00038.x","volume":"20","author":"H Massiou","year":"2000","unstructured":"Massiou H, MacGregor EA (2000) Evolution and treatment of migraine with oral contraceptives. Cephalalgia 20:170\u2013174. https:\/\/doi.org\/10.1046\/j.1468-2982.2000.00038.x","journal-title":"Cephalalgia"},{"key":"1167_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1783\/147118902101195974","volume":"28","author":"EA Macgregor","year":"2002","unstructured":"Macgregor EA, Hackshaw A (2002) Prevention of migraine in the pill-free interval of combined oral contraceptives: a double-blind, placebo-controlled pilot study using natural oestrogen supplements. J Fam Plann Reprod Health Care 28:27\u201331. https:\/\/doi.org\/10.1783\/147118902101195974","journal-title":"J Fam Plann Reprod Health Care"},{"key":"1167_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/head.12279","volume":"54","author":"DE Tepper","year":"2014","unstructured":"Tepper DE (2014) Headache toolbox: menstrual migraine. Headache 54:403\u2013408. https:\/\/doi.org\/10.1111\/head.12279","journal-title":"Headache"},{"key":"1167_CR20","doi-asserted-by":"publisher","unstructured":"Sacco S, Merki-Feld GS, \u00c6gidius KL, Bitzer J, Canonico M, Gantenbein AR, Kurth T, Lampl C, Lidegaard O, MacGregor EA, MaassenVanDenBrink A, Mitsikostas DD, Nappi RE, Ntaios G, Paemeleire K, Sandset PM, Terwindt GM, Vetvik KG, Martelletti P, European Headache Federation\u00a0(EHF), the European Society of Contraception and Reproductive Health (ESCRH) (2018) Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). J Headache Pain 19:76. https:\/\/doi.org\/10.1186\/s10194-018-0896-5","DOI":"10.1186\/s10194-018-0896-5"},{"key":"1167_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.thromres.2015.04.021","volume":"136","author":"Z Xu","year":"2015","unstructured":"Xu Z, Li Y, Tang S, Huang X, Chen T (2015) Current use of oral contraceptives and the risk of first-ever ischemic stroke: a meta-analysis of observational studies. Thromb Res 136:52\u201360. https:\/\/doi.org\/10.1016\/j.thromres.2015.04.021","journal-title":"Thromb Res"},{"key":"1167_CR22","doi-asserted-by":"publisher","unstructured":"Sacco S, Merki-Feld GS, \u00c6gidius KL, Bitzer J, Canonico M, Kurth T, Lampl C, Lidegaard O, MacGregor EA, MaassenVanDenBrink A, Mitsikostas DD, Nappi RE, Ntaios G, Sandset PM, Martelletti P, European Headache Federation (EHF), the European Society of Contraception and Reproductive Health (ESCRH) (2017) Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). J Headache Pain 18:108. https:\/\/doi.org\/10.1186\/s10194-017-0815-1","DOI":"10.1186\/s10194-017-0815-1"},{"key":"1167_CR23","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/14737175.2020.1730816","volume":"20","author":"R Ornello","year":"2020","unstructured":"Ornello R, Canonico M, Merki-Feld GS, Kurth T, Lidegaard O, MacGregor EA, Lampl C, Nappi RE, Martelletti P, Sacco S (2020) Migraine, low-dose combined hormonal contraceptives, and ischemic stroke in young women: a systematic review and suggestions for future research. Expert Rev Neurother 20:313\u2013317. https:\/\/doi.org\/10.1080\/14737175.2020.1730816","journal-title":"Expert Rev Neurother"},{"key":"1167_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/head.13229","volume":"58","author":"HU Sheikh","year":"2018","unstructured":"Sheikh HU, Pavlovic J, Loder E, Burch R (2018) Risk of stroke associated with use of estrogen containing contraceptives in women with migraine: a systematic review. Headache 58:5\u201321. https:\/\/doi.org\/10.1111\/head.13229","journal-title":"Headache"},{"key":"1167_CR25","doi-asserted-by":"publisher","unstructured":"Committee on Practice Bulletins\u2014Gynecology (2019) ACOG Practice Bulletin No. 206: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 133:e128\u2013e150. https:\/\/doi.org\/10.1097\/AOG.0000000000003072.","DOI":"10.1097\/AOG.0000000000003072"},{"key":"1167_CR26","doi-asserted-by":"publisher","unstructured":"Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, Paemeleire K, Olesen J, Peters M, Martelletti P (2019) Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain 20:57. https:\/\/doi.org\/10.1186\/s10194-018-0899-2","DOI":"10.1186\/s10194-018-0899-2"},{"key":"1167_CR27","unstructured":"World Health Organization (2015) Medical eligibility criteria for contraceptive use, 5th edition.https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/181468\/9789241549158_eng.pdf"},{"key":"1167_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1124\/jpet.115.227793","volume":"356","author":"L Shi","year":"2016","unstructured":"Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP, Immke DC, Wild KD, Xu C (2016) Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther 356:223\u2013231. https:\/\/doi.org\/10.1124\/jpet.115.227793","journal-title":"J Pharmacol Exp Ther"},{"key":"1167_CR29","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstrom Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377:2123\u20132132","journal-title":"N Engl J Med"},{"key":"1167_CR30","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ogc.2011.05.002","volume":"38","author":"EB Gold","year":"2011","unstructured":"Gold EB (2011) The timing of the age at which natural menopause occurs. Obstet Gynecol Clin N Am 38:425\u2013440. https:\/\/doi.org\/10.1016\/j.ogc.2011.05.002","journal-title":"Obstet Gynecol Clin N Am"},{"key":"1167_CR31","doi-asserted-by":"publisher","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, AMPP Advisory Group (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68:343\u2013349. https:\/\/doi.org\/10.1212\/01.wnl.0000252808.97649.21","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"1167_CR32","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1177\/0333102417739584","volume":"39","author":"A Labastida-Ramirez","year":"2019","unstructured":"Labastida-Ramirez A, Rubio-Beltran E, Villalon CM, MaassenVanDenBrink A (2019) Gender aspects of CGRP in migraine. Cephalalgia 39:435\u2013444. https:\/\/doi.org\/10.1177\/0333102417739584","journal-title":"Cephalalgia"},{"key":"1167_CR33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10194-005-0156-3","volume":"6","author":"AJ Dowson","year":"2005","unstructured":"Dowson AJ, Massiou H, Aurora SK (2005) Managing migraine headaches experienced by patients who self-report with menstrually related migraine: a prospective, placebo-controlled study with oral sumatriptan. J Headache Pain 6:81\u201387. https:\/\/doi.org\/10.1007\/s10194-005-0156-3","journal-title":"J Headache Pain"},{"key":"1167_CR34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.contraception.2017.10.003","volume":"97","author":"ML Kavanaugh","year":"2018","unstructured":"Kavanaugh ML, Jerman J (2018) Contraceptive method use in the United States: trends and characteristics between 2008, 2012 and 2014. Contraception 97:14\u201321. https:\/\/doi.org\/10.1016\/j.contraception.2017.10.003","journal-title":"Contraception"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01167-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-020-01167-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01167-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T23:06:33Z","timestamp":1627945593000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-020-01167-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1167"],"URL":"https:\/\/doi.org\/10.1186\/s10194-020-01167-6","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,3]]},"assertion":[{"value":"6 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the ethics committee or institutional review board at each clinical site, and all patients provided signed informed consent before the start of any study-related procedures. The study was conducted in accordance with the International Council for Harmonisation Good Clinical Practice Guidelines and conforms to the provisions of the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JMP is a consultant\/on advisory boards for Alder Biopharmaceuticals, Allergan, Amgen, Biohaven, Promius Pharma and receives research funding from NIH\/NIA K23AG049466-05. KP has received personal compensation from Allergan, Amgen\/Novartis, Eli Lilly, and Teva for consulting, serving on a scientific advisory board, and\/or speaking and is a clinical trial investigator for Amgen\/Novartis (erenumab), Eli Lilly (galcanezumab), and Autonomic Technologies Inc. (sphenopalatine ganglion stimulation). HG has received research support from Allergan, Amgen, Bayer, Novartis, Menarini, and Teva and is a speaker for Allergan, Novartis, and Teva. JB has nothing to disclose. AR is an advisor for Allergan, Amgen, Amneal, Assertio, Autonomic Technologies Inc., Biohaven, Cala Health, Neurolief, Promius, Satsuma, Teva, Theranica, Xoc, and Zosano and is on a speakers\u2019 bureau for Amgen and Teva. RK is a consultant for Amgen. FZ is an employee of Amgen Inc. HP and DDM are employees and stockholders of Amgen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}